Nektar Therapeutics (NKTR) Free Cash Flow Growth (3y) (2013 - 2026)
Nektar Therapeutics (NKTR) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
24.91% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
20.11% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
14.71% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Nektar Therapeutics |
1.51 Bn |
939.55 Mn |
3.16 Mn |
5.40% |
| Date | Value |
|---|
| Mar 31, 2026 |
5.40% |
| Dec 31, 2025 |
-3.73% |
| Sep 30, 2025 |
16.21% |
| Jun 30, 2025 |
15.46% |
| Mar 31, 2025 |
19.09% |
| Dec 31, 2024 |
33.33% |
| Sep 30, 2024 |
24.61% |
| Jun 30, 2024 |
23.96% |
| Mar 31, 2024 |
15.62% |
| Dec 31, 2023 |
22.19% |
| Sep 30, 2023 |
8.25% |
| Jun 30, 2023 |
15.80% |
| Mar 31, 2023 |
12.81% |
| Dec 31, 2022 |
23.28% |
| Sep 30, 2022 |
-3.95% |
| Jun 30, 2022 |
-4.94% |
| Mar 31, 2022 |
-2.29% |
| Dec 31, 2021 |
-7.64% |
| Sep 30, 2021 |
-12.43% |
| Jun 30, 2021 |
-27.86% |
